drugset
drugset / Trial / NCT07315373

Optimal Dose of Zanubrutinib to Treat Adult Immune Thrombocytopenia

NCT07315373 ↗

Phase 1 Not yet recruiting 60 enrolled Peking University People's Hospital
RandomizedParallel-groupSingle-blindTreatment

Summary

The goal of this clinical trial is to find the best dose of zanubrutinib when used together with high-dose dexamethasone for adults who are newly diagnosed with primary immune thrombocytopenia (ITP), and to learn how safe and effective this combination treatment is.

Timeline

Start
2025-12-25
Primary completion
2028-12-30
Completion
2029-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Zanubrutinib Small molecule 80 mg Oral
Subject Zanubrutinib Small molecule 160 mg Oral
Subject Zanubrutinib Small molecule 240 mg Oral
Background Dexamethasone Small molecule 40 mg Oral

Indications

autoimmune thrombocytopenia